Ochre Bio CSO Quin Wills (L) and CEO Jack O'Meara

Boehringer In­gel­heim inks chron­ic liv­er dis­ease re­search pact with Ochre Bio

Boehringer In­gel­heim is pay­ing Ochre Bio $35 mil­lion in up­front and near-term pay­ments to dis­cov­er new treat­ments for chron­ic liv­er dis­eases like meta­bol­ic dys­func­tion-as­so­ci­at­ed steato­hep­ati­tis.

Ochre Bio will be re­spon­si­ble for dis­cov­er­ing new tar­gets for treat­ments that could boost the liv­er’s self-re­pair abil­i­ties, ac­cord­ing to Mon­day’s an­nounce­ment. The goal of the part­ner­ship is to de­vel­op ther­a­pies that could slow, or even re­verse, liv­er dam­age in late-stage liv­er dis­eases.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.